Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/Valsartan vs Valsartan in HFrEF
NCT05881720Phase 4Completed
- Sponsor
- Damanhour University
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Damanhour University. Primary endpoint: Left Ventricular Ejection Fraction at 6 months. Started Jan 2022; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05881720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881720.